Trials Open for Broad-Acting Oncology Candidate - Chemotherapy Advisor
More in General Oncology News:
cer Care Costs Seem to Be Worth It
Read More >>
(ChemotherapyAdvisor)
– San Diego-based pharmaceutical company Marshall Edwards, Inc.,
announced today that it has received approval from the U.S. Food and
Drug Administration (FDA) for its Investigational New Drug (IND)
application for ME-344, the company's lead mitochondrial inhibitor.
A
Phase 1 clinical trial of intravenous ME-344 in patients with solid
refractory tumors is currently being initiated.
Data from a
preclinical study of NV-128, the metabolic precursor of
ME-344, demonstrated its ability to induce mitochondrial instability,
ultimately leading to cell death in otherwise chemotherapy-resistant
ovarian cancer stem cells.....
